International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064

ser



Downloads: 5 | Views: 92 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Analysis Study Research Paper | Cancer Science | Georgia | Volume 12 Issue 10, October 2023 | Rating: 5.6 / 10


Circulating Tumor Cells and cfDNA: Key Predictive Biomarkers in Non - Small Cell Lung Cancer Progression and Treatment

Alexandre Tavartkiladze [2] | Revaz Turmanidze | Gaiane Simonia [2] | Margalita Gogoladze | Pati Revazishvili [2] | George Dundua | Irine Andronikashvili


Abstract: Background/ Introduction: With the evolution of translational research in the realm of liquid biopsy, the relevance of circulating tumor cells (CTCs) and cfDNA or ctDNA is emerging. cfDNA is a fragment of DNA released into the plasma after cell apoptosis by lysis, carrying genome - wide DNA information. In contrast, ctDNA, a part of cfDNA, can be derived from primary tumors, metastases, and even CTCs. This novel approach has the potential for earlier lung cancer detection and monitoring of minimal residual disease (MRD) and resistance development, consequently paving the way for effective therapeutic decisions aimed at curing lung cancer. Materials and Methods: This article lays a comprehensive focus on CTCs as an advanced and validated marker in liquid biopsy. The ongoing research and discussions are targeted at attaining the new milestone of personalized (precision) medicine as a common standard of care for lung cancer. Results: The research findings indicate that CTCs, with their potential to serve as an effective biomarker in cancer, hold promise in recent advancements of cancer diagnosis and treatment. These cells could revolutionize the early detection and close monitoring of lung cancer, further informing appropriate therapeutic choices. Conclusion: The emerging utility of liquid biopsy, particularly CTCs and ctDNA, introduces a new dimension to personalized medicine in lung cancer treatment. The advancements summarized in this article highlight the promising prospects of this novel approach in achieving a standard of care in lung cancer, tailored to each patient's unique genetic profile.


Keywords: Non - Small Cell Lung Cancer, Circulating Tumor Cells, Cell - Free DNA, Early Diagnostic of Cancer, Personalized Treatment of Cancer


Edition: Volume 12 Issue 10, October 2023,


Pages: 1078 - 1081


How to Download this Article?

Type Your Valid Email Address below to Receive the Article PDF Link


Verification Code will appear in 2 Seconds ... Wait

Top